双成药业
(002693)
| 流通市值：32.63亿 | | | 总市值：32.93亿 |
| 流通股本：4.11亿 | | | 总股本：4.15亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 191,876,997.22 | 117,157,787.26 | 48,439,867.75 | 276,761,196.91 |
| 营业收入 | 191,876,997.22 | 117,157,787.26 | 48,439,867.75 | 276,761,196.91 |
| 二、营业总成本 | 181,485,017.29 | 111,712,392.98 | 50,126,030 | 267,592,610.62 |
| 营业成本 | 90,942,562.78 | 52,011,312.97 | 18,235,979.87 | 125,235,529.22 |
| 税金及附加 | 4,872,344.73 | 3,337,931.49 | 1,788,120.79 | 8,219,759.36 |
| 销售费用 | 12,997,570.94 | 8,327,839.77 | 3,617,528.15 | 30,511,219.69 |
| 管理费用 | 52,559,102.92 | 33,687,638.11 | 19,929,030.83 | 85,076,705.73 |
| 研发费用 | 9,119,936.23 | 6,618,133.17 | 2,617,980.65 | 8,093,599.46 |
| 财务费用 | 10,993,499.69 | 7,729,537.47 | 3,937,389.71 | 10,455,797.16 |
| 其中:利息费用 | 6,812,570.16 | 4,629,504.52 | 2,329,214.5 | 9,646,078.18 |
| 其中:利息收入 | 918,151.97 | 699,791.85 | 313,321.94 | 156,368.86 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 158,619.99 | 117,795.83 | 62,445.37 | 8,732.17 |
| 加:投资收益 | -190.69 | -190.69 | -86.05 | 562,709.58 |
| 资产处置收益 | 822,390.22 | - | - | 13,274.34 |
| 资产减值损失(新) | -175,347.97 | - | - | -5,241,265.81 |
| 信用减值损失(新) | 337,371.74 | 228,858.3 | 284,947.4 | -91,150.95 |
| 其他收益 | 6,618,345.03 | 3,192,231.8 | 815,346.06 | 4,438,901.84 |
| 四、营业利润 | 18,153,168.25 | 8,984,089.52 | -523,509.47 | 8,859,787.46 |
| 加:营业外收入 | 200.83 | 200.03 | - | 25,915.83 |
| 减:营业外支出 | 138,874.18 | 108,244 | 75,427.5 | 730,034.04 |
| 五、利润总额 | 18,014,494.9 | 8,876,045.55 | -598,936.97 | 8,155,669.25 |
| 减:所得税费用 | -51,036.82 | -51,036.82 | - | -764,411.42 |
| 六、净利润 | 18,065,531.72 | 8,927,082.37 | -598,936.97 | 8,920,080.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 18,065,531.72 | 8,927,082.37 | -598,936.97 | 8,920,080.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 22,448,015.9 | 13,627,788.39 | 3,448,212.09 | 19,043,164.44 |
| 少数股东损益 | -4,382,484.18 | -4,700,706.02 | -4,047,149.06 | -10,123,083.77 |
| 扣除非经常损益后的净利润 | 15,576,285.2 | 10,899,601.29 | 2,853,829.74 | 15,227,653.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.03 | 0.01 | 0.05 |
| (二)稀释每股收益 | 0.05 | 0.03 | 0.01 | 0.05 |
| 八、其他综合收益 | -2,883.38 | -2,217.92 | -1,457.51 | 4,281.36 |
| 归属于母公司股东的其他综合收益 | -2,883.38 | -2,217.92 | -1,457.51 | 4,281.36 |
| 九、综合收益总额 | 18,062,648.34 | 8,924,864.45 | -600,394.48 | 8,924,362.03 |
| 归属于母公司股东的综合收益总额 | 22,445,132.52 | 13,625,570.47 | 3,446,754.58 | 19,047,445.8 |
| 归属于少数股东的综合收益总额 | -4,382,484.18 | -4,700,706.02 | -4,047,149.06 | -10,123,083.77 |
| 公告日期 | 2026-10-29 | 2026-08-22 | 2026-04-29 | 2026-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |